

# Emerging Isotopes Pipeline Analysis and Global Market - Forecast to 2029

<https://marketpublishers.com/r/E033C801E648EN.html>

Date: July 2022

Pages: 234

Price: US\$ 4,950.00 (Single User License)

ID: E033C801E648EN

## Abstracts

“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

### Market Analysis

In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total

addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.

Emerging Isotopes related deals analysis.

Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).

### Pipeline Analysis

Pipeline Analysis based Isotopes

Pipeline Analysis based on indications

Pipeline analysis based on targets

Pipeline analysis based on leading players

### Key Players Analysis

The key player's analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

Key players overview

Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)

Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)

## Contents

### 1 EXECUTIVE SUMMARY

### 2 INTRODUCTION

- 2.1 REPORT SCOPE
- 2.2 REPORT DESCRIPTION
- 2.3 PIPELINE ANALYSIS
- 2.4 KEY PLAYERS ANALYSIS
- 2.5 STAKEHOLDERS
- 2.6 RESEARCH METHODOLOGY

### 3 EMERGING ISOTOPES

- 3.1 INTRODUCTION
- 3.2 PIPELINE ANALYSIS OVERVIEW
  - 3.2.1 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS
  - 3.2.2 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS
- 3.3 DEMAND ANALYSIS OF EMERGING ISOTOPES
- 3.4 LUTETIUM (Lu-177)
  - 3.4.1 GEP-NET MARKET ANALYSIS
  - 3.4.2 PROSTATE CANCER MARKET ANALYSIS
  - 3.4.3 LUTETIUM PIPELINE ANALYSIS
    - 3.4.3.1 Demand and Production Analysis of Lutetium-177 (Lu-177)
  - 3.4.4 Lu-177 – DEALS, APPROVALS, AND FUNDING
- 3.5 GALLIUM (Ga-68)
  - 3.5.1 SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (Ga-68)
  - 3.5.2 Ga-68 MARKET
  - 3.5.3 GALLIUM-68 (Ga-68) PIPELINE ANALYSIS
  - 3.5.4 Ga-68 – DEALS, APPROVALS, AND FUNDING
- 3.6 ACTINIUM (Ac-225)
  - 3.6.1 PRODUCTION ANALYSIS OF ACTINIUM-225 (Ac-225) AND BISMUTH-213 (Bi-213)
  - 3.6.2 ACTINIUM (Ac-225) PIPELINE ANALYSIS
  - 3.6.3 Ac-225 – DEALS, APPROVALS, AND FUNDING
- 3.7 YTTRIUM (Y-90)
  - 3.7.1 YTTRIUM (Y-90) PIPELINE ANALYSIS
  - 3.7.2 Y-90 – DEALS, APPROVALS, AND FUNDING

- 3.8 ZIRCONIUM (Zr-89)
  - 3.8.1 ZIRCONIUM (Zr-89) PIPELINE ANALYSIS
  - 3.8.2 Zr-89 – DEALS, APPROVALS, AND FUNDING
- 3.9 LEAD (Pb-212)/BISMUTH (Bi-212)
  - 3.9.1 LEAD (Pb-212) PIPELINE ANALYSIS
  - 3.9.2 Pb-212 – DEALS, APPROVALS, AND FUNDING
- 3.10 COPPER (Cu-64)
  - 3.10.1 COPPER 64 (Cu-64) PIPELINE ANALYSIS
  - 3.10.2 Cu-64 – DEALS, APPROVALS, AND FUNDING
- 3.11 COPPER (Cu-67)
  - 3.11.1 COPPER 67 (Cu-67) PIPELINE ANALYSIS
  - 3.11.2 Cu-67 – DEALS, APPROVALS, NEWS, AND FUNDING
- 3.12 RHENIUM (Re-186)
  - 3.12.1 RHENIUM (Re-186) PIPELINE ANALYSIS
  - 3.12.2 Re-186 – DEALS, APPROVALS, NEWS, AND FUNDING
- 3.13 RHENIUM-188 (Re-188)
  - 3.13.1 RHENIUM (Re-188) PIPELINE ANALYSIS
  - 3.13.2 Re-188 – DEALS, APPROVALS, NEWS, AND FUNDING
- 3.14 ASTATINE (At-211)
  - 3.14.1 ASTATINE (At-211) PIPELINE ANALYSIS
  - 3.14.2 At-211 – DEALS, APPROVALS, NEWS, AND FUNDING
- 3.15 HOLMIUM (Ho-166)
  - 3.15.1 HOLMIUM (Ho-166) PIPELINE ANALYSIS
  - 3.15.2 Ho-166 – DEALS, APPROVALS, AND NEWS
- 3.16 RADIUM (Ra-223)
  - 3.16.1 SUPPLY CHAIN ANALYSIS OF RADIUM-223 (Ra-223)
  - 3.16.2 RADIUM (Ra-223) PIPELINE ANALYSIS
- 3.17 RADIUM (Ra-224)
  - 3.17.1 RADIUM (Ra-224) PIPELINE ANALYSIS
  - 3.17.2 Ra-224 – DEALS, APPROVALS, NEWS, AND FUNDING
- 3.18 THORIUM (Th-227)
  - 3.18.1 THORIUM (Th-227) PIPELINE ANALYSIS
- 3.19 SCANDIUM (Sc-43, 44, 47)
- 3.20 TERBIUM (Tb-149,152,155, 161)
- 3.21 ARSENIC (As-72, As-74, As-77)
- 3.22 IRON (Fe-52)
- 3.23 BARIUM-128 (Ba-128)
- 3.24 BARIUM-131 (Ba-131)

## **4 MAJOR PLAYER PROFILES**

4.1 BOSTON SCIENTIFIC CORPORATION (BSC)

4.2 CLARITY PHARMACEUTICALS LIMITED

4.3 CURIUM SAS

4.4 ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG (PENTIXAPHARM, GMBH)

4.5 FUSION PHARMACEUTICALS, INC.

4.6 ITM ISOTOPE TECHNOLOGIES MUNICH SE

4.7 NOVARTIS AG

4.8 ORANO MED, LLC

4.9 PLUS THEAPEUTICS, INC.

4.10 POINT BIOPHARMA GLOBAL, INC.,

4.11 RADIOMEDIX, INC.,

4.12 TELIX PHARMACEUTICALS, LTD.

## List Of Tables

### LIST OF TABLES

TABLE 1 EMERGING ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 2 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS (CANCER)

TABLE 3 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS (NON-CANCER)

TABLE 4 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON MAJOR PLAYERS

TABLE 5 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON UNIVERSITIES/HOSPITALS

TABLE 6 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES

TABLE 7 DIAGNOSTICS PIPELINE ANALYSIS BASED ON INDICATIONS

TABLE 8 DIAGNOSTICS PIPELINE ANALYSIS BASED ON MAJOR PLAYERS

TABLE 9 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON UNIVERSITIES/HOSPITALS

TABLE 10 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES

TABLE 11 THERAPEUTICS PIPELINE ANALYSIS BASED ON INDICATIONS

TABLE 12 THERAPEUTICS PIPELINE ANALYSIS BASED ON MAJOR PLAYERS

TABLE 13 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON UNIVERSITIES/HOSPITALS

TABLE 14 LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 15 GEP-NET GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 16 GEP-NET NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2022

TABLE 17 GEP-NET THERAPY ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2021-2029) (NO.S),

TABLE 18 GEP-NET TOTAL ADDRESSABLE MARKET (TAM) FOR GEP-NET (\$MN)

TABLE 19 GEP-NET TOTAL DEMAND FOR DOSES IN CURIE

TABLE 20 GEP-NET NUMBER OF DOSES SOLD

TABLE 21 PROSTATE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2029) (\$MN)

TABLE 22 PROSTATE CANCER NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2022

TABLE 23 LU-177 PROSTATE CANCER THERAPY ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2022-2029) (NO.S),

TABLE 24 LU-177 PROSTATE CANCER THERAPY TOTAL ADDRESSABLE MARKET (TAM) (2022-2029)(\$MN)

TABLE 25 LU-177 PROSTATE CANCER TOTAL DEMAND FOR DOSES IN CURIE (2022-2029)

TABLE 26 LU-177 PROSTATE CANCER NUMBER OF DOSES SOLD

TABLE 27 LUTETIUM (LU-177) SUPPLIERS AND PRODUCTION CAPACITY

TABLE 28 GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 29 GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS

TABLE 30 ACTINIUM (AC-225) CURRENT AND FUTURE SUPPLIERS

TABLE 31 YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 32 RENAL CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2024-2029) (\$MN)

TABLE 33 ZR-89 RENAL CANCER DIAGNOSTIC ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2022-2029) (NO.S),

TABLE 34 ZR-89 RENAL CANCER DIAGNOATICS TOTAL ADDRESSABLE MARKET (TAM) (2022-2029)(\$MN)

TABLE 35 ZR-89 TOTAL DEMAND FOR DOSES IN CURIE (2022-2029)

TABLE 36 NET GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 37 CU-64 NET DIAGNOSTIC ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2021-2029) (NO.S),

TABLE 38 CU-64 NET DIAGNOATICS TOTAL ADDRESSABLE MARKET (TAM) (2021-2029)(\$MN)

TABLE 39 CU-64 TOTAL DEMAND FOR DOSES IN CURIE (2021-2029)

TABLE 40 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 41 ASTATINE (AT-211) CURRENT SUPPLIERS

TABLE 42 RADIUM (RA-223) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

## List Of Figures

### LIST OF FIGURES

FIGURE 1 EMERGING ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN) AND MARKET SHARE 2022 (%)

FIGURE 2 EMERGING ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN), CAGR (%)

FIGURE 3 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON PHASES

FIGURE 4 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON MAJOR PLAYERS

FIGURE 5 EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON CANDIDATES AND APPLICATION

FIGURE 6 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES

FIGURE 7 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS

FIGURE 8 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON MODALITY

FIGURE 9 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES

FIGURE 10 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS

FIGURE 11 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS, BASED ON THE TYPE OF RADIATION

FIGURE 12 GLOBAL LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)

FIGURE 13 NORTH AMERICA LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)

FIGURE 14 EUROPE LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)

FIGURE 15 ASIA-PACIFIC LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)

FIGURE 16 ROW LU-177 BASED THERAPY MARKET PENETRATION, (2021) (%)

FIGURE 17 PROSTATE CANCER GLOBAL MARKET PENETRATION, (2022) (%)

FIGURE 18 NORTH AMERICA PROSTATE CANCER MARKET PENETRATION, (2022) (%)

FIGURE 19 EUROPE PROSTATE CANCER MARKET PENETRATION, (2022) (%)

FIGURE 20 ASIA-PACIFIC PROSTATE CANCER MARKET PENETRATION, (2022) (%)

FIGURE 21 ROW PROSTATE CANCER MARKET PENETRATION, (2022) (%)

FIGURE 22 LU-177 PIPELINE ANALYSIS BASED ON PHASES

FIGURE 23 LU-177 PIPELINE ANALYSIS BASED ON INDICATIONS

FIGURE 24 LU-177 PIPELINE ANALYSIS BASED ON TARGETS



FIGURE 25 LU-177 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 26 LU-177 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 27 LU-177 RIT PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 28 LU-177 RIT PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 29 LU-177 RIT PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 30 LU-177 PRRT PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 31 LU-177 PRRT PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 32 LU-177 PRRT PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 33 DIRECT METHOD (CARRIER ADDED)  
FIGURE 34 INDIRECT METHOD (NON-CARRIER ADDED)  
FIGURE 35 GA-68: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)  
FIGURE 36 SUPPLY CHAIN OF GE-68/GA-68 GENERATOR  
FIGURE 37 GA-68 PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 38 GA-68 PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 39 GA-68 PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 40 GA-68 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 41 GA-68 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 42 AC-225 PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 43 AC-225 PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 44 AC-225 PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 45 AC-225 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 46 AC-225 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 47 Y-90 PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 48 Y-90 PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 49 Y-90 PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 50 Y-90 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 51 Y-90 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 52 ZR-89 PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 53 ZR-89 PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 54 ZR-89 PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 55 ZR-89 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 56 ZR-89 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 57 PB-212 PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 58 PB-212 PIPELINE ANALYSIS BASED ON INDICATIONS  
FIGURE 59 PB-212 PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 60 PB-212 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 61 PB-212 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 62 CU-64 PIPELINE ANALYSIS BASED ON PHASES  
FIGURE 63 CU-64 PIPELINE ANALYSIS BASED ON INDICATIONS

FIGURE 64 CU-64 PIPELINE ANALYSIS BASED ON TARGETS  
FIGURE 65 CU-64 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS  
FIGURE 66 CU-64 PIPELINE ANALYSIS BASED ON MOLECULE TYPE  
FIGURE 67 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON  
REGION, (2022 V/S 2029) (%)  
FIGURE 68 BOSTON SCIENTIFIC CORPORATION (BSC)  
FIGURE 69 CLARITY PHARMACEUTICALS LIMITED  
FIGURE 70 CURIUM SAS  
FIGURE 71 ECKERT & ZIEGLER (PENTIXAPHARM, GMBH)  
FIGURE 72 FUSION PHARMACEUTICALS, INC.  
FIGURE 73 ITM (ISOTOPE TECHNOLOGIES MUNICH)  
FIGURE 74 NOVARTIS AG  
FIGURE 75 ORANO MED, LLC  
FIGURE 76 PLUS THEAPEUTICS, INC.  
FIGURE 77 POINT BIOPHARMA GLOBAL, INC.  
FIGURE 78 RADIOMEDIX, INC.  
FIGURE 79 TELIX PHARMACEUTICALS, LTD.

## I would like to order

Product name: Emerging Isotopes Pipeline Analysis and Global Market - Forecast to 2029

Product link: <https://marketpublishers.com/r/E033C801E648EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E033C801E648EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970